← Back to Search

Unknown

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Salt Lake City, UT
Phase 1
Waitlist Available
Research Sponsored by Vertex Pharmaceuticals Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new drug called VX-548 in healthy people to see how it behaves in their bodies and if it is safe. Researchers want to understand how the drug moves through and affects the body before using it on patients with specific conditions.

See full description

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2021 Phase 2 trial • 303 Patients • NCT05034952
30%
Nausea
12%
Constipation
11%
Dizziness
11%
Vomiting
7%
Headache
4%
Hypotension
3%
Hyperhidrosis
1%
Hypoxia
1%
Laryngeal stenosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
HB/APAP
VX-548 High Dose
VX-548 Low Dose

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: VX-548Experimental Treatment1 Intervention
Participants will be randomized to receive a single dose of VX-548 in 1 of 6 treatment sequences with 3 dosing periods to assess different fed conditions and timing of meal administration on the PK of VX 548. There will be a 14 day washout period between each dosing period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VX-548
2022
Completed Phase 3
~3750

Find a Location

Closest Location:ICON Salt Lake City· Salt Lake City, UT· 1513 miles

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Vertex Pharmaceuticals IncorporatedLead Sponsor
263 Previous Clinical Trials
35,670 Total Patients Enrolled
22 Trials studying Pain
1,387 Patients Enrolled for Pain

Media Library

VX-548 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT05851157 — Phase 1
Pain Research Study Groups: VX-548
Pain Clinical Trial 2023: VX-548 Highlights & Side Effects. Trial Name: NCT05851157 — Phase 1
VX-548 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05851157 — Phase 1
~26 spots leftby Mar 2026